跳至主要内容
临床试验/NCT06789510
NCT06789510已完成不适用

Treatment of Peyronie's Disease With Platelet-Rich Plasma: A Pilot Study

Herlev Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年3月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Platelet Concentration in the PRP

研究概览

简要总结

The purpose of this pilot study is to optimize a planned randomized, double-blind, placebo-controlled clinical trial evaluating the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase. The pilot study aims to identify potential challenges in the practical execution of the clinical trial, particularly regarding PRP preparation and the blinding process. Furthermore, it seeks to evaluate the effects of PRP injections.

详细描述

The study protocol is structured such that participants, after being informed about the project and providing consent, will attend a baseline visit where relevant data will be collected from the participant, questionnaires, the patient's medical record, and through an objective examination. Subsequently, participants will attend weekly injection sessions for 6 weeks, during which they will receive 3 PRP injections and 3 saline injections (placebo) in a randomized order. Three months after the final injection, participants will attend a follow-up visit, where the final data will be collected. Analysis will then be conducted.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

The participant and the investigator/treating doctor will be masked. The syringes will be covered. Only the care provider who prepare the PRP will not be masked.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •18 years or older
  • •Be able to provide written informed consent
  • •Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase).
  • •Penile curvature of 30-95 degrees

排除标准

  • •Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors
  • •Hourglass malformation
  • •Severely calcified plaques where injection is considered unfeasible
  • •History of priapism.
  • •History of penile fracture.
  • •Previous treatment for PD with injections and/or surgery.

研究组 & 干预措施

Platelet Rich Plasma (PRP)

Experimental

Each participant will receive 3 PRP injections over the 6-week period, with weekly injections in a randomized sequence. The RedCap randomization module will ensure that each participant receives 3 injections of each type.

干预措施: Autologous Platelet Rich Plasma (Other)

Saline Solution (Placebo)

Placebo Comparator

Each participant will receive 3 saline injections over the 6-week period, with weekly injections in a randomized sequence. The RedCap randomization module will ensure that each participant receives 3 injections of each type.

In addition, Platelet-Rich Plasma (PRP) will be prepared but, instead of being injected, it will be analyzed for platelet count.

干预措施: Saline solution (Other)

结局指标

主要结局

Platelet Concentration in the PRP

时间窗: The 6 week intervention period.

In the placebo sessions, the Platelet-Rich Plasma (PRP) sample (prepared using the Magellan Autologous Platelet Separator) will be sent for analysis of platelet concentration levels to ensure the quality of the PRP.

Evaluation of the Blinding Process

时间窗: The 6 week intervention period.

After each injection, both the administering physician and the participant will be asked to state whether they believe the injection contained PRP or saline. They will also be asked to justify their response, which will allow for adjustments to the practical implementation of the blinding process in the Randomized Controlled Trial (RCT), if necessary.

次要结局

  • Changes in Plaque Size(From enrollment to 3 months post intervention.)
  • Adverse Events(From the first injection to the 3 months post intervention follow-up.)
  • Degree Changes in Penile Curvature.(From enrollment to 3 months post intervention.)
  • Changes in the Peyronie's Disease Questionnaire (PDQ)(From enrollment to 3 months post intervention.)
  • Changes in the Erection Hardness Score (EHS)(From enrollment to 3 months post intervention.)
  • Changes in the Major Depression Inventory (MDI)(From enrollment to 3 months post intervention.)
  • The Ability to Engage in Sexual Intercourse (question)(From enrollment to 3 months post intervention.)
  • Preference for Surgical Intervention (question)(From enrollment to 3 months post intervention.)
  • Satisfaction(From enrollment to 3 months post intervention.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mikael Heering

Medical Doctor, Clinical Assistant

Herlev Hospital

研究点 (1)

Loading locations...

相似试验